Subsidiary of GIANT BIOGENE (02367) received the "Medical Device Registration Certificate of the People's Republic of China" for the recombined Type I 1 subtype collagen freeze-dried fiber product.

GIANT BIOGENE (02367) announced that its wholly-owned subsidiary, Shaanxi GIANT BIOGENE Technology Co., Ltd., received the "Medical Device Registration Certificate of the People's Republic of China" (Registration Certificate Number: National Machinery Standard 20253132049) issued by the China National Medical Products Administration for its freeze-dried fibrous product of recombined type I1 subtype collagen protein. This product, with recombinant collagen protein as the main ingredient, is used for filling facial dermal tissue to correct dynamic wrinkles on the forehead, including frown lines, forehead lines, and crow's feet. This product is the first facial injectable product in China containing recombined type I natural sequence collagen protein, officially approved through a joint review by the medical device and drug administrations. The approval of this product reflects the core competitiveness of the company in technology research and development and industrialization, further enriching the product categories and bringing new opportunities for the company's business development in the skin rejuvenation market. In the future, the company will gradually promote the market launch of this product according to its business plan, and will synergize with existing products, brands, and channels to provide consumers with a more diverse experience, continuously solidifying the company's leading position in the health and beauty field.